News & Press
Israel's WeissBio raises $35M for antibody-based targeted drug delivery across the blood-brain barrier
Calcalist Tech4/20/2026·04/20/26🌐 Europe
Summary
Tel Aviv-based WeissBio closed a $35M Series A for their proprietary transferrin receptor-targeting antibody platform that ferries therapeutic payloads across the blood-brain barrier. Initial indications target glioblastoma and Alzheimer's disease. Their lead conjugate shows 15x higher brain penetration than free drug in preclinical models.
Why it matters
The blood-brain barrier remains the primary obstacle to CNS drug delivery. A 15x penetration improvement in preclinical models, if it holds in humans, could revive numerous CNS drug candidates previously abandoned due to poor brain exposure.
#Alzheimers#Industry#Israel#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in